Abbott reports second-quarter 2023 results; increases outlook for underlying base business

Sales of $10.0 billion driven by strong underlying base business performance reported sales decreased 11.4 percent due to anticipated decline in covid-19 testing-related sales versus prior year organic sales growth for underlying base business of 11.5 percent, led by medical devices, established pharmaceuticals and nutrition continues to strengthen portfolio with new product approvals and expanded reimbursement coverage abbott park, ill., july 20, 2023 /prnewswire/ -- abbott (nyse: abt) today announced financial results for the second quarter ended june 30, 2023.
ABT Ratings Summary
ABT Quant Ranking